We partner with leading clinical researchers and laboratory professionals to deliver breakthrough after breakthrough. Each one helps improve care for millions of patients living with autoimmune diseases through enhanced quality and efficiency.
What’s our latest breakthrough?
QUANTA Flash HMGCR help diagnose a form of statin-associated necrotizing myopathy which is positive by anti-HMGCR and not usually detected by other myopathy/myositis biomarkers.
How are we advancing the quality and efficiency of autoimmune testing?
NOVA Lite DAPI reagents, used in combination with NOVA View, provide improved quality for IFA testing with an automated process that can reduce labor hours and hands-on time in the lab.
How do we increase detection rates for APS?
QUANTA Lite anti-PS/PT is designed to increase detection rates for diagnosing APS by improving sensitivity, without sacrificing specificity. It can even be used to aid diagnosis when patients have already started treatment with anti-coagulation therapy.
QUANTA Flash RF IgM and IgA receive FDA clearance
Inova Diagnostics, a world leader in autoimmune disease diagnostic systems and reagents for the clinical laboratory, is pleased to announce the 510(k) clearance of QUANTA Flash® Rheumatoid Factor (RF) IgM and QUANTA Flash RF IgA assays by the US Food and Drug Administration (FDA). These chemiluminescent assays complement Inova Diagnostics previously cleared QUANTA Flash CCP3 assay that detects anti-citrullinated peptide antibodies (ACPA) and expands the number of FDA-cleared assays available on BIO-FLASH®, a random access chemiluminescent system.
Inova Diagnostics is hosting a breakfast workshop at AACC 2019
Closing the patient care gap in autoimmunity: The clinical value of new biomarkers
Clinicians, laboratorians and patients have one goal in common- improving healthcare. Autoimmune diseases are challenging to diagnose due to the seronegative gap, often leading to delays in treatment for the patient.
With the development of new biomarkers and technologies, patients can receive a more accurate, earlier diagnosis including valuable information regarding risk stratification. We will discuss new biomarkers for autoimmune disease and present an advanced technology for multi-analyte testing.
It All Starts With People
Our talent is, without a question, our most important asset. Our employees are the face of Inova, and they represent our values in their day-to-day interactions with our stakeholders